For research use only. Not for therapeutic Use.
CB-103(CAT: I017530) represents an innovative breakthrough as a first-in-class oral protein-protein interaction (PPI) inhibitor targeting the NOTCH transcriptional activation complex. By disrupting this critical interaction, CB-103 exerts its potent anti-tumor effects. Its unique mechanism of action highlights its potential in modulating aberrant NOTCH signaling pathways associated with oncogenesis.
| Catalog Number | I017530 |
| CAS Number | 218457-67-1 |
| Molecular Formula | C₁₅H₁₈N₂O |
| Purity | ≥95% |
| Target | Stem Cell/Wnt |
| Reference | [1]. Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.<br>[2]. R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.<br>[3]. Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.<br>[4]. Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. |
